Role of epigenetics in cellular reprogramming; from iPSCs to disease modeling and cell therapy

被引：4

作者：

Li, Yong ^{[1
]}

Darabi, Radbod ^{[2
]}

机构：

[1] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Orthopaed Surg, BioMed Engn, Kalamazoo, MI 49008 USA

[2] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis IMM, McGovern Med Sch, Ctr Stem Cell & Regenerat Med, 1825 Pressler St,SRB 630 C, Houston, TX 77030 USA

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2022年 / 123卷 / 02期

关键词：

differentiation; disease modeling; epigenetics; iPSCs; regenerative medicine; reprogramming; DNA METHYLATION PATTERNS; PLURIPOTENT STEM-CELLS; TRANSCRIPTIONAL REGULATION; DEMETHYLATION; EXPRESSION; CHROMATIN; ESTABLISHMENT; METABOLISM; GENOME; MEMORY;

D O I：

10.1002/jcb.30164

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Epigenetics play a fundamental role in induced pluripotent stem cell (iPSC) technology due to their effect on iPSC's reprogramming efficiency and their subsequent role in iPSC differentiation toward a specific lineage. Epigenetics can skew the differentiation course of iPSCs toward a specific lineage based on the epigenetic memory of the source cells, or even lead to acquisition of new cell phenotypes, due to its aberrations during reprogramming. This viewpoint discusses key features of the epigenetic process during iPSC reprogramming/differentiation and outlines important epigenetic factors that need to be considered for successful generation and differentiation of iPSCs for downstream applications.

引用

页码：147 / 154

页数：8

共 50 条

[1] Epigenetics, cardiovascular disease, and cellular reprogramming
Al-Hasani, Keith
Mathiyalagan, Prabhu
El-Osta, Assam
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2019, 128 : 129 - 133
[2] Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease
Marei, Hany E.
Khan, Muhammad Umar Aslam
Hasan, Anwarul
CELLULAR & MOLECULAR BIOLOGY LETTERS, 2023, 28 (01)
[3] Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy
Csobonyeiova, Maria
Polak, Stefan
Danisovic, Lubos
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
[4] Recent approaches and challenges in iPSCs: modeling and cell-based therapy of Alzheimer's disease
Csobonyeiova, Maria
Polak, Stefan
Danisovic, L'ubos
REVIEWS IN THE NEUROSCIENCES, 2016, 27 (05) : 457 - 464
[5] Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease
Hany E. Marei
Muhammad Umar Aslam Khan
Anwarul Hasan
Cellular & Molecular Biology Letters, 28
[6] Reprogramming cancer cells: A novel approach for cancer therapy or a tool for disease-modeling?
Yilmazer, Acelya
de Lazaro, Irene
Taheri, Hadiseh
CANCER LETTERS, 2015, 369 (01) : 1 - 8
[7] Modeling Alexander disease with patient iPSCs reveals cellular and molecular pathology of astrocytes
Kondo, Takayuki
Funayama, Misato
Miyake, Michiyo
Tsukita, Kayoko
Era, Takumi
Osaka, Hitoshi
Ayaki, Takashi
Takahashi, Ryosuke
Inoue, Haruhisa
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2016, 4
[8] Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies
Chen, Zhiguo
AGING AND DISEASE, 2015, 6 (06): : 499 - 503
[9] iPSCs as a Platform for Disease Modeling, Drug Screening, and Personalized Therapy in Muscular Dystrophies
Ortiz-Vitali, Jose L.
Darabi, Radbod
CELLS, 2019, 8 (01)
[10] Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell-based remyelination therapies
McCaughey-Chapman, Amy
Connor, Bronwen
JOURNAL OF NEUROSCIENCE RESEARCH, 2023, 101 (06) : 1000 - 1028

← 1 2 3 4 5 →